Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
Journal Article (Journal Article;Review)
Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.
Full Text
Duke Authors
Cited Authors
- Gurbel, PA; Tantry, US
Published Date
- March 2008
Published In
Volume / Issue
- 9 / 3
Start / End Page
- 324 - 336
PubMed ID
- 18311669
International Standard Serial Number (ISSN)
- 1472-4472
Language
- eng
Conference Location
- England